Advertisement for orthosearch.org.uk
Results 1 - 2 of 2
Results per page:
Orthopaedic Proceedings
Vol. 92-B, Issue SUPP_III | Pages 434 - 434
1 Jul 2010
Krieg A Mani M Speth B Stalley P
Full Access

This study reviews the implantation of extracorporally irradiated autografts as a treatment modality and alternative for pelvic Ewing’s Sarcoma.

We identified 13 cases between 1994 and 2004 (7 male, 6 female), with mean age 14 years (6.5–34.5). The disease free survival was 69% overall, (75% excluding one case initially treated elsewhere) with a mean follow-up of 6.1 years (3.1 – 8.2). Four patients died with distant metastases at a mean time of 17 months (13–23).

Functional results showed a median MST-Score of 86% (IQR 68.5 to 91.5), a median TES-Score 85% (IQR78.5 to 93.5) and a median Harris Hip-Score 89% (IQR 82.5 to 96.5).

Solid bony union was observed at all osteotomy sites. Consolidation was achieved after median 6 months (IQR 5 to 7).

There were three complications (23%) which required operative intervention, one (8%) due to infection, which required removal of the autograft.

Advantages with this technique include ideal fit in the defect and thus promotes healing through greater contact at osteotomy junctions. It avoids early and late loosening and/or breakage of a prosthesis. It acts as a biological bridge for creeping substitution and bony incorporation in the defect. It allows re-attachment of tendons and ligaments, and thus preserves anatomic relationships. There is no risk of disease transmission or immunological reactions. It is cost effective and convenient in any institution with radiotherapeutic equipment.

We conclude this is an appropriate treatment option for localised and resectable pelvic Ewing Sarcoma.


The Journal of Bone & Joint Surgery British Volume
Vol. 91-B, Issue 3 | Pages 395 - 400
1 Mar 2009
Krieg AH Mani M Speth BM Stalley PD

We review the treatment of pelvic Ewing’s sarcoma by the implantation of extracorporeally-irradiated (ECI) autografts and compare the outcome with that of other reported methods.

We treated 13 patients with ECI autografts between 1994 and 2004. There were seven males and six females with a median age of 15.7 years (interquartile range (IQR) 12.2 to 21.7). At a median follow-up of five years (IQR 1.8 to 7.4), the disease-free survival was 69% overall, and 75% if one patient with local recurrence after initial treatment elsewhere was excluded. Four patients died from distant metastases at a mean of 17 months (13 to 23). There were three complications which required operative intervention; one was a deep infection which required removal of the graft. The functional results gave a mean Musculoskeletal Tumor Society score of 85% (60% to 97%), a mean Toronto extremity salvage score of 86% (69% to 100%) and a mean Harris hip score of 92 (67 to 100).

We conclude that ECI grafting is a suitable form of treatment for localised and resectable pelvic Ewing’s sarcoma.